Myhibbin, mycophenolate mofetil oral suspension
Named-patient access overview. Myhibbin is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Myhibbin
Myhibbin (mycophenolate mofetil oral suspension) is manufactured by Azurity Pharmaceuticals and was approved by the US FDA in 2024 for prophylaxis of organ rejection in adult and pediatric recipients of allogeneic kidney, heart, or liver transplants, used in combination with cyclosporine and corticosteroids. It is a purine synthesis inhibitor that works by selectively and reversibly blocking inosine monophosphate dehydrogenase (IMPDH), suppressing de novo guanosine nucleotide synthesis in T and B lymphocytes. The clinical value of the Azurity formulation is practical: a ready-to-use oral suspension for adult and pediatric patients who cannot reliably swallow capsules or tablets.
Mycophenolate mofetil carries an FDA boxed warning covering embryofetal toxicity (including first-trimester pregnancy loss and congenital malformations), increased risk of lymphoma and other malignancies, and increased risk of serious infections; the prescribing information also requires that prescribers be familiar with transplant immunosuppression. For international patients, Myhibbin may be coordinated through Named Patient Program or personal-import pathways with the destination country's regulator and the patient's treating transplant team handling the documentation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Myhibbin
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Myhibbin for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Myhibbin is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Myhibbin in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Myhibbin
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.